JP2024536581A - 中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 - Google Patents
中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 Download PDFInfo
- Publication number
- JP2024536581A JP2024536581A JP2024523674A JP2024523674A JP2024536581A JP 2024536581 A JP2024536581 A JP 2024536581A JP 2024523674 A JP2024523674 A JP 2024523674A JP 2024523674 A JP2024523674 A JP 2024523674A JP 2024536581 A JP2024536581 A JP 2024536581A
- Authority
- JP
- Japan
- Prior art keywords
- cbd
- asd
- subject
- abc
- irritability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271015P | 2021-10-22 | 2021-10-22 | |
| US63/271,015 | 2021-10-22 | ||
| PCT/US2022/078449 WO2023070045A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536581A true JP2024536581A (ja) | 2024-10-04 |
| JP2024536581A5 JP2024536581A5 (enExample) | 2025-10-27 |
Family
ID=84358575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523674A Pending JP2024536581A (ja) | 2021-10-22 | 2022-10-20 | 中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240342198A1 (enExample) |
| EP (1) | EP4419091A1 (enExample) |
| JP (1) | JP2024536581A (enExample) |
| KR (1) | KR20240093852A (enExample) |
| CN (1) | CN118284412A (enExample) |
| AU (1) | AU2022373753A1 (enExample) |
| CA (1) | CA3235677A1 (enExample) |
| IL (1) | IL312328A (enExample) |
| MX (1) | MX2024004766A (enExample) |
| WO (1) | WO2023070045A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| CA3300266A1 (en) * | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| WO2019224824A1 (en) * | 2018-05-24 | 2019-11-28 | To Pharmaceuticals Llc | Cannabis-based compositions for the treatment of autistic spectrum disorders |
| US20210369643A1 (en) * | 2020-05-26 | 2021-12-02 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol |
| BR112022026044A2 (pt) * | 2020-06-29 | 2023-03-07 | Zynerba Pharmaceuticals Inc | Tratamento de síndrome do x frágil com canabidiol |
| WO2022103639A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
-
2022
- 2022-10-20 CN CN202280077354.9A patent/CN118284412A/zh active Pending
- 2022-10-20 CA CA3235677A patent/CA3235677A1/en active Pending
- 2022-10-20 IL IL312328A patent/IL312328A/en unknown
- 2022-10-20 WO PCT/US2022/078449 patent/WO2023070045A1/en not_active Ceased
- 2022-10-20 EP EP22803457.5A patent/EP4419091A1/en active Pending
- 2022-10-20 JP JP2024523674A patent/JP2024536581A/ja active Pending
- 2022-10-20 MX MX2024004766A patent/MX2024004766A/es unknown
- 2022-10-20 KR KR1020247016925A patent/KR20240093852A/ko active Pending
- 2022-10-20 AU AU2022373753A patent/AU2022373753A1/en active Pending
-
2024
- 2024-04-22 US US18/642,059 patent/US20240342198A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022373753A1 (en) | 2024-05-09 |
| CN118284412A (zh) | 2024-07-02 |
| EP4419091A1 (en) | 2024-08-28 |
| IL312328A (en) | 2024-06-01 |
| WO2023070045A1 (en) | 2023-04-27 |
| KR20240093852A (ko) | 2024-06-24 |
| US20240342198A1 (en) | 2024-10-17 |
| CA3235677A1 (en) | 2023-04-27 |
| MX2024004766A (es) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226373B2 (en) | Treatment of fragile X syndrome with cannabidiol | |
| JP7807870B2 (ja) | うつ病の治療のためのエスケタミン | |
| US12582664B2 (en) | Treatment of fragile x syndrome with cannabidiol | |
| US20240342198A1 (en) | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance | |
| JP2023528354A (ja) | カンナビジオールを用いた自閉症スペクトラム障害の処置 | |
| US20260027137A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| US20230000793A1 (en) | Treatment of 22q11.2 deletion syndrome with cannabidiol | |
| US20230000792A1 (en) | Treatment of 22q11.2 deletion syndrome with cannabidiol | |
| US20250177322A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| US20240390295A1 (en) | Methods for treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251017 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251017 |